12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PBT2: Extension study start

Next month, Prana will begin a 12-month, open-label extension study of 250 mg, once-daily, oral PBT2 in patients with prodromal or mild AD who completed the 12-month, double-blind, placebo-controlled, Australian Phase II IMAGINE...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >